LUXEMBOURG–(BUSINESS WIRE)–Regulatory news:
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces the closing of the acquisition of Ascend Clinical, LLC (Ascend), the largest independent renal dialysis testing laboratory in the United States. Founded in 2000, Ascend operates a state-of-the-art laboratory in Sunnyvale, California and employs 170 people. The company provides highly automated chemical, hematology, microbiology and virology testing services to dialysis clinics and hospitals across the United States. The company also offers water and dialysate testing, providing greater safety to the dialysis patient community and facilitating successful regulatory audits and surveys. Ascend’s core competencies and client relationships complement the Eurofins network’s broad portfolio of pre- and post-transplant services, which will result in better and broader service offerings for clients.
The acquisition further strengthens the Eurofins network’s footprint in transplant trials and associated renal care, broadening its clinical client base. Ascend, in return, gains access to Eurofins’ extensive laboratory network, analytical portfolio and established industrial relationships. Patti Hunsader, the current COO of Ascend, will assume the role of President of Ascend Clinical. The company’s current leadership will remain in place, continuing to drive the organization’s growth as part of Eurofins’ clinical diagnostics business line in the United States.
Comment from Dr. Gilles Martin, CEO of Eurofins: “This transaction further extends our efforts to provide best-in-class testing care to patients in the renal and transplant fields. We look forward to providing Ascend customers with the access the capabilities of the Eurofins network, and to support Ascend in strengthening and growing the important services it provides to patients.
Comment from Patti Hunsader, COO of Ascend: “We are excited to join forces with the Eurofins network. This partnership creates exciting opportunities to leverage our combined expertise and resources to positively impact the lives of the patients we serve.”
Integrating Ascend’s expertise and customer base with Eurofins’ geographic reach, technological capabilities and experience will improve the standard of care provided to patients nationwide.
Notes to editors:
About Eurofins “the global leader in bioanalysis
Eurofins is testing life. The Eurofins Scientific SE network of independent companies believes it is a global leader in food, environmental, pharmaceutical and cosmetic product testing and contract research services in drug discovery, forensics, advanced materials sciences and agri-food sciences. It is also a market leader in certain genomics testing and laboratory services and clinical trial support, as well as biopharmaceutical contract development and manufacturing. It also has a rapidly developing presence in highly specialized molecular clinical diagnostic tests and in vitro diagnostic products.
With approx. With 62,000 employees in a decentralized, entrepreneurial network of more than 900 laboratories in more than 1,000 companies in 62 countries, Eurofins offers a portfolio of more than 200,000 analytical methods to evaluate safety, identity, composition, authenticity, origin, the traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in vitro diagnostic products.
The wide range of services of Eurofins companies is important for the health and safety of people and our planet. Continuous investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our goal of providing our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support customers’ increasingly stringent quality and safety standards and the growing demands of regulators, as well as the evolving needs of healthcare providers around the world.
The Eurofins network has grown very strongly since its inception and its strategy is to continue to expand its technology portfolio and geographic reach. Through research and development and acquisitions, its companies draw on the latest developments in biotechnology and analytical chemistry to offer its customers unique analytical solutions.
Eurofins Scientific SE shares are listed on the Euronext Paris stock exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
About Ascend
Ascend Clinical was founded in Northern California in 2000 as a clinical reference laboratory specializing in kidney disease testing services. Ascend’s dedication to advanced technology and innovative solutions has expanded its services to cover a wide range of in vitro diagnostics. With a state-of-the-art laboratory located in Sunnyvale, California, and offices in Colorado, Ascend is one of the largest independent laboratories in the United States, committed to supporting physicians and improving patient care. More information at www.aclab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402530392/en/
For more information please visit www.eurofins.com or contact:
Investor relations
Eurofins Scientific SE
Telephone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
Source: Eurofins Scientific